Abstract
Background Acute myocarditis is a disease with variable prognosis, ranging from complete recovery to end-stage heart failure (HF) and death. The aim of this study was to examine the risk of mortality and HF in patients with suspected acute myocarditis (AM) in comparison to patients hospitalized for unexplained acute chest pain (ACP).
Methods We used the SWEDEHEART-registry to identify patients >16 years admitted to hospital between 1 January 1998 and 31 December 2018 with either AM or ACP. Risks of all-cause mortality and development of HF were calculated and compared by use of adjusted Cox regression analyses.
Results A total of 3,792 patients with AM and 109,934 patients with ACP were included. Median follow-up time was 7.8 years (Q1, Q3; 3.4, 12.3). AM patients were younger compared to ACP patients, median age 37 years (Q1, Q3; 26, 52) vs 59 years (Q1, Q3; 49, 69), and more likely to be men (79.9% vs 51.4%, p <0.001). Comorbidity burden was lower within the AM cohort. Chest pain was the most common presenting symptom in both groups. Mortality rate at 30 days (OR 3.75, 95% CI 1.9-7.3, p<0,001) as well as long term (OR 2.0, 95% CI 1.69-2.39, p <0.001) were significantly higher among AM patients and AM patients were more likely to develop HF during follow-up (OR 2.3, 95% CI 1.81-2.93, p<0,001).
Conclusions AM patients had a worse short -and long-term outcome compared with ACP. The risk for development of HF was higher for AM patients even after the first year.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trial
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Swedish Ethical Review Authority
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
